David R Shaffer
Overview
Explore the profile of David R Shaffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fizazi K, Retz M, Petrylak D, Goh J, Perez-Gracia J, Lacombe L, et al.
J Immunother Cancer
. 2022 Aug;
10(8).
PMID: 35977756
Background: CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and...
2.
Lee C, Shah A, Rasco D, Rao A, Taylor M, Di Simone C, et al.
Lancet Oncol
. 2021 Jun;
22(7):946-958.
PMID: 34143969
Background: Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune...
3.
Petrylak D, Loriot Y, Shaffer D, Braiteh F, Powderly J, Harshman L, et al.
Clin Cancer Res
. 2021 Feb;
27(12):3360-3369.
PMID: 33568344
Purpose: Atezolizumab [anti-programmed death-ligand 1 (anti-PD-L1)] is well tolerated and efficacious in multiple cancers, but has not been previously evaluated in metastatic castration-resistant prostate cancer (mCRPC). This study examined the...
4.
Galsky M, Shahin M, Jia R, Shaffer D, Gimpel-Tetra K, Tsao C, et al.
JCO Clin Cancer Inform
. 2019 Jan;
1:1-10.
PMID: 30657386
Purpose: Clinical trials are critical to informing cancer care but often are hampered by slow accrual and lack of generalizability because of poor geographic accessibility. We tested the feasibility of...
5.
Welch T, Shaffer D, Feldman D
Case Rep Nephrol Dial
. 2017 Jun;
7(2):49-54.
PMID: 28612006
A 30-year-old man with severe antenatal Bartter syndrome, diagnosed and treated in infancy, developed testicular carcinoma. Despite the known renal complications of cisplatin, this drug was used for his chemotherapy...
6.
Balar A, Galsky M, Rosenberg J, Powles T, Petrylak D, Bellmunt J, et al.
Lancet
. 2016 Dec;
389(10064):67-76.
PMID: 27939400
Background: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand...
7.
Rathkopf D, Larson S, Anand A, Morris M, Slovin S, Shaffer D, et al.
Cancer
. 2015 Jul;
121(21):3853-61.
PMID: 26178426
Background: The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested...
8.
Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster K, et al.
Nat Genet
. 2013 Jun;
45(7):739-746.
PMID: 23727861
Zbtb7a has previously been described as a powerful proto-oncogene. Here we unexpectedly demonstrate that Zbtb7a has a critical oncosuppressive role in the prostate. Prostate-specific inactivation of Zbtb7a leads to a...
9.
Morse J, Shaffer D, Williamson G, Dooley W, Schulz R
Psychol Aging
. 2011 May;
27(1):211-8.
PMID: 21604890
The burden of providing informal care to a family member can lead to caregiver depression and potentially harmful caregiving behavior. Given the interpersonal nature of caregiving, the relationship between caregivers...
10.
Shaffer D, Dooley W, Williamson G
Psychol Aging
. 2007 Sep;
22(3):494-504.
PMID: 17874950
This research tested the proposition that the oft-reported relation between caregiver mental health outcomes (i.e., resentment, depression) and potentially harmful caregiver behavior (PHB) would be mediated or moderated by caregiver...